全文获取类型
收费全文 | 1948篇 |
免费 | 153篇 |
国内免费 | 11篇 |
学科分类
医药卫生 | 2112篇 |
出版年
2023年 | 10篇 |
2022年 | 8篇 |
2021年 | 28篇 |
2020年 | 17篇 |
2019年 | 25篇 |
2018年 | 45篇 |
2017年 | 30篇 |
2016年 | 32篇 |
2015年 | 44篇 |
2014年 | 54篇 |
2013年 | 78篇 |
2012年 | 67篇 |
2011年 | 87篇 |
2010年 | 73篇 |
2009年 | 97篇 |
2008年 | 91篇 |
2007年 | 76篇 |
2006年 | 61篇 |
2005年 | 52篇 |
2004年 | 54篇 |
2003年 | 45篇 |
2002年 | 63篇 |
2001年 | 42篇 |
2000年 | 50篇 |
1999年 | 47篇 |
1998年 | 57篇 |
1997年 | 61篇 |
1996年 | 76篇 |
1995年 | 61篇 |
1994年 | 52篇 |
1993年 | 59篇 |
1992年 | 31篇 |
1991年 | 15篇 |
1990年 | 30篇 |
1989年 | 50篇 |
1988年 | 42篇 |
1987年 | 46篇 |
1986年 | 43篇 |
1985年 | 34篇 |
1984年 | 29篇 |
1983年 | 17篇 |
1982年 | 27篇 |
1981年 | 17篇 |
1980年 | 12篇 |
1979年 | 7篇 |
1978年 | 7篇 |
1977年 | 12篇 |
1976年 | 14篇 |
1975年 | 13篇 |
1967年 | 4篇 |
排序方式: 共有2112条查询结果,搜索用时 78 毫秒
61.
Histamine reduces boron neutron capture therapy‐induced mucositis in an oral precancer model 下载免费PDF全文
62.
63.
Human platelet membrane glycoproteins IIb and IIIa (GPIIb and IIIa) were incorporated into phospholipid vesicles by the reverse-phase technique to assess the ability of GPIIb and IIIa to function as a Ca2+ channel. Movement of Ca2+ across the lipid bilayer was quantitated by injection of proteoliposomes with encapsulated Fura-2 into Ca2+ buffers and measurement of Fura-2 fluorescence as an indicator of Ca2+ influx. Reciprocally, to assess the function of proteins in an inside-out orientation, Ca2+-loaded vesicles were injected into Ca2+-free buffer and Ca2+ efflux monitored by a calcium electrode. Incorporation of the IIb-IIIa complex produced significant facilitation of Ca2+ movement across the lipid bilayer. No net transmembrane Ca2+ movement was seen with dissociated IIb and IIIa. Movement of Ca2+ was proportional to the transmembrane Ca2+ gradient. Ca2+ movement into the vesicles was inversely proportional to extravesicular NaCl from 25 to 150 mmol/L, analogous to several studies in the intact platelet. Adenosine triphosphate had no effect on Ca2+ movement into or out of the vesicles. Specific inhibition of a Ca2+ shift into the vesicles was seen with M148, a monoclonal antibody to IIb/IIIa, while no inhibition was observed with a panel of other anti-IIb/IIIa monoclonal antibodies. This suggests that a specific site on the complex or orientation of the complex is essential for calcium channel function. These data demonstrate that the GPIIb/IIIa complex can serve as a passive Ca2+ channel across a phospholipid bilayer and has the potential to play a role in Ca2+ flux across the platelet plasma membrane. 相似文献
64.
Hasegawa DK; Bennett AJ; Coccia PF; Ramsay NK; Nesbit ME; Krivit W; Edson JR 《Blood》1980,56(4):585-595
Factor V deficiency has been identified in 8 of 8 patients 7--20 yr of age, with Philadelphia-positive (Ph1+) chronic myelogenous leukemia (CML). In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation. In 3 patients, factor V activity rose 10%--12% (0.10--0.12 U/ml) after the infusion of 28--31 ml/kg body weight of fresh frozen plasma (FFP). The rise persisted less than 14 hr. The mean measured postinfusion rise in factor V was 18% of the expected rise calculated from the volume of FFP infused in the patients' plasma volume. In 4 patients, a small transient rise in factor V activity occurred after splenectomy or plateletpheresis. Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph1+ CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation. Factor V deficiency was retrospectively observed in 6 of 20 patients, ages 20--80 yr, with Ph1+ CML and 3 of 6 patients with other myeloproliferative disorders. The factor V deficiency appears to be associated with the large myeloid- megakaryocytic cell mass characteristic of CML and other myeloproliferative disorders. 相似文献
65.
66.
D.A. Dyment E. Sell M.R. Vanstone A.C. Smith D. Garandeau V. Garcia S. Carpentier E. Le Trionnaire F. Sabourdy C.L. Beaulieu J.A. Schwartzentruber H.J. McMillan J. Majewski D.E. Bulman T. Levade K.M. Boycott 《Clinical genetics》2014,86(6):558-563
Spinal muscular atrophy with progressive myoclonic epilepsy (SMA‐PME) is a recently delineated, autosomal recessive condition caused by rare mutations in the N‐acylsphingosine amidohydrolase 1 (acid ceramidase) ASAH1 gene. It is characterized by motor neuron disease followed by progressive myoclonic seizures and eventual death due to respiratory insufficiency. Here we report an adolescent female who presented with atonic and absence seizures and myoclonic jerks and was later diagnosed as having myoclonic‐absence seizures. An extensive genetic and metabolic work‐up was unable to arrive at a molecular diagnosis. Whole exome sequencing (WES) identified two rare, deleterious mutations in the ASAH1 gene: c.850G>T;p.Gly284X and c.456A>C;p.Lys152Asn. These mutations were confirmed by Sanger sequencing in the patient and her parents. Functional studies in cultured fibroblasts showed that acid ceramidase was reduced in both overall amount and enzymatic activity. Ceramide level was doubled in the patient's fibroblasts as compared to control cells. The results of the WES and the functional studies prompted an electromyography (EMG) study that showed evidence of motor neuron disease despite only mild proximal muscle weakness. These findings expand the phenotypic spectrum of SMA‐PME caused by novel mutations in ASAH1 and highlight the clinical utility of WES for rare, intractable forms of epilepsy. 相似文献
67.
68.
69.
70.
非酒精性脂肪性肝炎(non—alcoholicsteatohepatitis,NASH)现已成为肝移植愈来愈重要的基础肝病。鉴于晚期NASH患者常并存多种影响肝移植转归的临床问题,而至今尚无针对NASH患者进行肝移植的评估和治疗指南,为此英国移植学会(British Transplant Society,BTS)邀请相关专家制定了指南,以指导肝移植前后NASH患者的处理。 相似文献